A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Stopped This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.

Conditions

• Non-small Cell Lung Cancer
• NSCLC

Interventions

• DRUG: Tislelizumab
• DRUG: Ociperlimab
• DRUG: Pembrolizumab
• DRUG: Placebo

Sponsor

BeiGene